Biote Q1 revenue $44.8M (+20.7%), net loss $21.4M; launches warrant exchange offer

biote Corp.

2023-Q1 EPS reported -$0.39 revenue$44,843,000

Revenue $44.8M (+20.7% YoY); gross margin 69.1% (+220 bps).
Net loss $(21.4)M ($(0.39) per share) vs net income $9.4M in Q1 2022.
Adjusted EBITDA $13.1M (+12.4% YoY); maintains FY 2023 guidance $190-200M revenue, $56-60M adj EBITDA.
Offer: each outstanding warrant exchanged for 0.23 common shares; consent to convert remaining at 0.207.
Parties representing 19.4% of public warrants and 59.3% of private warrants have agreed to tender.

item 2.02 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

biote Corp. reported first quarter ended March 31, 2023 results: revenue $44.8 million, net income $(21.4) million, EPS $(0.39) per share. Guidance reaffirmed.

Period: first quarter ended March 31, 2023
Revenue: $44.8 million
Net income: $(21.4) million
EPS: $(0.39) per share
Guidance: reaffirmed
Result: reported results

Exact text from the filing

hormone therapy, today announced financial results for the first quarter ended March 31, 2023. First Quarter 2023 Financial Highlights, year-over-year: • Revenue of $44.8 million, a 20.7% increase • Gross profit margin of 69.1%, a 220-basis point increase • Net loss of $(21.4) million and GAAP loss per share of $(0.39), primarily reflecting the impact

View on SEC.gov

59 earnings releases filed in the last 30 days. Browse all earnings releases →

biote Corp. filing history →

Source: SEC EDGAR

accession 0001193125-23-139561

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.